Circulating versus cellular biomarkers of inflammation in Type 1 diabetes: The superiority of C-reactive protein

Cytokine

Volumn 60, Issue 1, 2012, Pages 318-320

  Jialal, Ishwarlal ^a   Devaraj, Sridevi ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD14 ANTIGEN; CD16 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

ARTERIAL WALL THICKNESS; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CYTOKINE RELEASE; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MACROPHAGE; MACROPHAGE ACTIVATION; MICROALBUMINURIA; MONOCYTE; MONOCYTOSIS; NONHUMAN; NOTE; PRIORITY JOURNAL;

CELL PROLIFERATION; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; MALE; MONOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865429737     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.05.011     Document Type: Note

References (33)

1. Libby P., Nathan D.M., Abraham K., et al. National heart, lung, and blood institute, national institute of diabetes and digestive and kidney diseases: working group on cardiovascular complications of Type 1 diabetes mellitus. Circulation 2005, 11:3489-3493.
2. Bassuk S.S., Rifai N., Ridker P.M. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 2004, 29:439-493.
3. Bruno G., Fornengo P., Novelli G., et al. C-reactive protein and 5-year survival in type 2 diabetes: the Casale Monferrato study. Diabetes 2009, 58:926-933.
4. Schulze M.B., Rimm E.B., Li T., Rifai N., Stampfer M.J., Hu F. C-reactive protein and incident cardiovascular events in diabetes. Diabetes Care 2004, 27:889-894.
5. Soinio M., Marnemi J., Laakso M., Lehto S., Ronnemaa T. High sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes. Diabetes Care 2006, 29:329-333.
6. Bierhaus A., Schiekofer S., Schwaninger M., Andrassy M., Humpert P.M., Chen J., et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001, 50(12):2792-2808.
7. Pickup J.C. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004, 27(3):813-823.
8. Devaraj S., Glaser N., Griffen S., Wang-Polagruto J., Miguelino E., Jialal I. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes 2006, 55(3):774-779.
9. Devaraj S., Cheung A.T., Jialal I., Griffen S.C., Nguyen D., Glaser N., et al. Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes 2007, 56(11):2790-2796.
10. Schalkwijk C.G., Poland D.C., van Dijk W., Kok A., Emeis J.J., Dräger A.M., et al. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 1999, 42(3):351-357.
11. Schram M.T., Chaturvedi N., Schalkwijk C.G., Fuller J.H., Stehouwer C.D. EURODIAB prospective complications study group. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes-the EURODIAB prospective complications study. Diabetologia 2005, 48:370-378.
12. Hayaishi-Okano R., Yamasaki Y., Katakami N., Ohtoshi K., Gorogawa S., Kuroda A., et al. Elevated C- reactive protein associates with early-stage carotid atherosclerosis in young subjects with type 1 diabetes. Diabetes Care 2002, 25(8):1432-1438.
13. Sundell J., Rönnemaa T., Laine H., Raitakari O.T., Luotolahti M., Nuutila P., et al. High-sensitivity C-reactive protein and impaired coronary vasoreactivity inyoung men with uncomplicated type 1 diabetes. Diabetologia 2004, 47(11):1888-1894.
14. Colhoun H., Schalkwijk C., Rubens M.B., Stehouwer C.D. C-reactive protein in type 1 diabetes and its relationship to coronary artery calcification. Diabetes Care 2002, 25:1813-1817.
15. Targher G., Bertolini L., Zoppini G., Zenari L., Falezza G. Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy. Diabet Med 2005, 22(8):999-1004.
16. Hansen T.K., Forsblom C., Saraheimo M., et al. Association between mannose-binding lectin, high-sensitivity C-reactive protein and the progression of diabetic nephropathy in type 1 diabetes. Diabetologia 2010, 53:1517-1524.
17. Jialal I., Kaur H., Devaraj S. Human C-reactive protein accentuates macrophage activity in biobreeding diabetic rats. J Diabetes Complications 2012, [PMID: 22520400].
18. Liu F., Chen H.Y., Huang X.R., Chung A.C., Zhou L., Fu P., et al. C-reactive protein promotes diabetic kidney disease in a mouse model of type 1diabetes. Diabetologia 2011, 54(10):2713-2723.
19. Moreno P.R., Murcia A.M., Palacios I.F., Leon M.N., Bernardi V.H., Fuster V., et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 2000, 102(18):2180-2184.
20. Mackman N. Lipopolysaccharide induction of gene expression in human monocytic cells. Immunol Res 2000, 21:247-251.
21. Mantovani A. Molecular pathways linking inflammation and cancer. Curr Mol Med 2010, 10:369-373.
22. Mantovani A., Locati M. Orchestration of macrophage polarization. Blood 2009, 114:3135-3136.
23. Mantovani A., Garlanda C., Locati M. Macrophage diversity and polarization in atherosclerosis: a question of balance. Arterioscler Thromb Vasc Biol 2009, 29:1419-1423.
24. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003, 3:23-35.
25. Geissmann F., Gordon S., Hume D.A., Mowat A.M., Randolph G.J. Unravelling mononuclear phagocyte heterogeneity. Nat Rev Immunol 2010, 10:453-460.
26. Gautier E.L., Jakubzick C., Randolph G.J. Regulation of the migration and survival of monocyte subsets by chemokine receptors and its relevance to atherosclerosis. Arterioscler Thromb Vasc Biol 2009, 29:1412-1418.
27. Swirski F.K., Weissleder R., Pittet M.J. Heterogeneous in vivo behavior of monocyte subsets in atherosclerosis. Arterioscler Thromb Vasc Biol 2009, 29:1424-1432.
28. Geissmann F., Auffray C., Palframan R., Wirrig C., Ciocca A., Campisi L., et al. Blood monocytes: distinct subsets, how they relate to dendritic cells, and their possible roles in the regulation of T-cell responses. Immunol Cell Biol 2008, 86:398-408.
29. van de Veerdonk F.L., Netea M.G. Diversity: a hallmark of monocyte society. Immunity 2010, 33:289-291.
30. Saha P., Geissmann F. Toward a functional characterization of blood monocytes. Immunol Cell Biol 2011, 89:2-4.
31. Devaraj S., Jialal I. C-reactive protein polarizes human macrophages to an M1 phenotype and inhibits transformation to the M2 phenotype. Arterioscler Thromb Vasc Biol 2011, 31(6):1397-1402.
32. Ohashi K., Parker J.L., Ouchi N., Higuchi A., Vita J.A., Gokce N., et al. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J Biol Chem 2010, 285(9):6153-6160.
33. Mysliwska J., Smardzewski M., Marek-Trzonkowska N., Mysliwiec M., Raczynska K. Expansion of CD14+CD16+ monocytes producing TNF-α in complication-free diabetes type 1 juvenile onset patients. Cytokine 2012, PMID: 22484242.